Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Email alerts

Application overview

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Reset

13 trials match this view; 11 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 374 across 13 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Recorded study-start years

201711
201922
202011
202111
202211
202311
202422
202544

Current indexed registry status

Completed1010
Recruiting33

Reported research conditions

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

13 matching registry records. Dates are registry milestones, not promised results announcements.
TrialSponsor and phaseStatusEnrollmentStart / primary completion / completionResearch workflow
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects

NCT06884514

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2026-06-25

24

ACTUAL

2025-04-03
2026-05-13
2026-05-28
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)

NCT05883540

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress
University Hospital, Basel, Switzerland

PHASE2

Recruiting

Registry updated 2026-04-29

60

ESTIMATED

2024-06-09
2027-09
2028-05
Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants

NCT06180759

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2026-04-02

17

ACTUAL

2025-01-23
2025-09-29
2025-11-06
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)

NCT06796361

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-05-28

16

ESTIMATED

2025-04-21
2026-08
2026-08
Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).

NCT05695495

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2025-04-11

36

ACTUAL

2024-06-12
2025-02-02
2025-03-04
Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)

NCT06899334

Healthy
University Hospital, Basel, Switzerland

PHASE1

Recruiting

Registry updated 2025-03-27

24

ESTIMATED

2025-04-01
2026-08-01
2026-08-01
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

NCT05523401

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2025-03-05

24

ACTUAL

2023-08-16
2024-10-20
2024-11-05
Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over Study

NCT05384678

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2024-04-25

24

ACTUAL

2022-11-15
2024-03-08
2024-03-13
Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy Subjects

NCT04227756

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2024-01-24

32

ACTUAL

2020-05-19
2022-09-02
2022-09-02
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness

NCT04849013

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2023-03-29

16

ACTUAL

2021-08-11
2023-03-27
2023-03-27
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study

NCT03153579

Patients · Anxiety Disorders
University Hospital, Basel, Switzerland

PHASE2

Completed

Registry updated 2021-12-22

46

ACTUAL

2017-06-23
2021-12-15
2021-12-15
Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin in a Random-order Placebo-controlled Cross-over Study in Healthy Subjects

NCT03604744

Healthy
University Hospital, Basel, Switzerland

EARLY_PHASE1

Completed

Registry updated 2021-04-27

28

ACTUAL

2019-03-27
2021-04-10
2021-04-15
Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

NCT03912974

Healthy
University Hospital, Basel, Switzerland

PHASE1

Completed

Registry updated 2020-12-01

27

ACTUAL

2019-07-04
2020-11-26
2020-11-26

Reported research facilities

University Hospital BaselBasel, Canton of Basel-City, Switzerland
University Hospital Basel, Division of Clinical Pharmacology and ToxicologyBasel, Switzerland
University Hospital Geneva, Palliative medicine departmentCollonge-Bellerive, Switzerland
Spital Uster AG, Division of Internal MedicineUster, Switzerland
University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative CareZurich, Switzerland
Clinical Pharmacology & Toxicology, University Hospital BaselBasel, Switzerland
Clinical Trial UnitBasel, Canton of Basel-City, Switzerland
University HospitalBasel, Switzerland
Universtity Hospital BaselBasel, Switzerland
University Hospital Basel, Clinical Trial UnitBasel, Canton of Basel-City, Switzerland
Private Practice P.GasserSolothurn, Canton of Solothurn, Switzerland

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.